Agoracom Blog Home

Archive for the ‘Tetra Bio-Pharma Inc.’ Category

BMO $BMO.ca marks first foray by a major Canadian bank in #marijuana sector with $175M deal $TBP.ca $N.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 2:42 PM on Thursday, January 18th, 2018

  • Bank of Montreal broke new ground Wednesday for the “Big Five” Canadian lenders with its participation in a major marijuana deal
  • Canopy Growth Corp., Canada’s largest licensed producer of medical cannabis, announced an approximately $175-million bought-deal offering Wednesday

Smiths Falls, Ont.-based Canopy Growth Corp., Canada’s largest licensed producer of medical cannabis, announced an approximately $175-million bought-deal offering Wednesday of a little more than five million shares of the company.

Canopy noted in a release that GMP Securities LP and Bank of Montreal-owned BMO Capital Markets were leading the transaction for the company as joint bookrunners, marking the first time a major Canadian bank has helped head an equity financing for a publicly traded company in the medical marijuana industry.

“This is the first time a major Canadian bank-owned brokerage has participated in a cannabis securities issue,” wrote Chris Damas, editor of the BCMI Cannabis Report.

A spokesperson for Canopy confirmed that the transaction marked the first such foray by a Big Five Canadian bank.

“Although this does not guarantee participation in the cannabis sector by all six of the largest Canadian Schedule 1 banks (BMO had already been a banker for cannabis companies), it is very positive for the sector, all things being equal,” Damas added.

Other major Canadian banks have yet to dive into the country’s growing cannabis sector in the same way BMO has, and are likely hesitant to do so given their significant business in the United States, where marijuana is still illegal under federal law. But some banks, including BMO, have provided business accounts for cannabis companies, according to Bloomberg.

That stance may now be starting to soften amid a fundraising spree in the Canadian marijuana industry, which had been taking place without the country’s biggest banks. Companies involved in the already legal medical pot business have been seeking funding to serve the coming recreational market set to be legalized by the federal government this summer.

Royal Bank of Canada told the Financial Post in a statement last week that it “currently does not provide banking services to companies engaged in the production and distribution of marijuana.”

“We recognize that the legislative landscape is evolving and we are undergoing a review of our policies,” added the lender.

A spokesperson for Bank of Nova Scotia told the Post on Friday that “we must balance that with our commitment to effectively manage all business risks.”

“While we understand there is a robust debate in Canada and abroad, our priority is to manage risk for our customers and stakeholders to ensure they are protected,” said Scotiabank’s Rick Roth in an email. “Should there be significant change to industry legislation or regulation, we will revisit our risk assessment and make risk policy adjustments if warranted.”

Toronto-Dominion Bank and the Canadian Imperial Bank of Commerce either declined to comment or had yet to respond as of Thursday morning.

Canopy said its agreement with the underwriters includes an over-allotment option for them, allowing for the purchase of up to 759,000 additional shares at the offering price of $34.60 per share, worth nearly $26.3 million. The company said that the deal is expected to close on Feb. 7, subject to some conditions, and that the net proceeds will be used “for capital expenditures for capacity expansion, working capital, and general corporate requirements.”

Source: http://business.financialpost.com/investing/bank-of-montreal-marks-first-for-major-canadian-lenders-with-175m-marijuana-deal

Tetra Bio-Pharma $TBP.ca Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil) $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:13 AM on Tuesday, January 16th, 2018

Logo tetrabiopharma rgb web

  • Received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD),
  • Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005

OTTAWA, ONTARIO–(Jan. 16, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.

According to Health Canada data1, the annual Canadian cannabis oil production for medical purposes was 22,766 kg between October 1st 2016 and September 30th 2017, and is growing continuously. In the third quarter of 2017, it grew 24% from Q2 (Apr-Jun) to Q3 (Jul-Sep)1. According to an Eight Capital analysis2, the cannabis oil market is expected to reach 1.5B$ in 2024.

The launch of this trial is the first step in Tetra’s plans to commercialize natural health products with its partners. The corporation will develop cannabis-based supplements for commercialization under the Natural Health Product regulations in Canada and in other countries where regulatory authorities have a recognized pathway for approval and commercialization of such products. The trial will eventually include formulations that will be registered as drugs under Health Canada’s TPD regulatory pathway. “Tetra Bio-Pharma Inc. seeks to become an important player in the retail market post legalization and this clinical trial is part of the sales and marketing strategy required to effectively penetrate the lucrative pharmacy and health stores retail markets,” states Bernard Fortier, CEO of Tetra.

Tetra’s vision is to develop an evidence-based approach, thereby allowing pharmacists to dispense these medicines to patients in need. Despite the growing popularity of cannabis oils, physicians and pharmacists across Canada are still hesitant to support the use of these products because of the lack of data supporting its medical use. Dr. Guy Chamberland, Chief Science Officer, commented: “This trial is part of Tetra’s corporate strategy to develop the science required to commercialize safe and efficacious cannabis oil products post-legalization and to create innovative oral drug formulations for the development of medicines in the management of pain, anxiety and the treatment of cancer.”

In that respect, Tetra’s scientific team is supporting the strategy by initiating a phase 1 clinical trial to characterize the safe use of these cannabis oil medicines in humans. Tetra has worked with Altasciences Clinical Research for the preparation of the Clinical Trial Application (CTA) for the conduct of a double-blind phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple daily doses of cannabis (Delta-9-tetrahydrocannabinol/Cannabidiol) oil capsules administered to healthy human volunteers. Health Canada issued a No Objection Letter for the conduct of the phase I clinical trial on January 12nd, 2018. Altasciences Clinical Research will be initiating the clinical trial activities in the coming weeks. The cannabis oil is manufactured by Tetra’s partner, Aphria Inc.

1: Health Canada Market Data, [https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/market-data.html] 2: Cannabis Sector, Eight Capital Estimates, July 2017About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com

Canadian #cannabis producers set their sights on global domination $N.ca $TBP.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 11:10 AM on Friday, January 5th, 2018

  • Medical research forcing an end to prohibition
  • “I’ve never experienced anything like this,” says Ranjeev Dhillon, a corporate lawyer and partner at the law firm Bennett Jones. Most of his practice now centres on the cannabis export business.
  • In recent months, more than a dozen countries have legalized medical marijuana

Medical marijuana consumers in Prague rang in 2018 with a new Canadian import, Tilray Milled Cannabis, a high THC marijuana product grown on Vancouver Island.

The Czech Republic is just the latest nation to sell Canadian weed, joining Germany, Australia, New Zealand and a growing list of other nations which are turning to Canada as a safe and legal source for medical grade cannabis.

In recent months, more than a dozen countries have legalized medical marijuana. New laws are pending in at least a dozen more as national regulators and even the World Health Organization recognize legitimate medical uses for a drug which had long been banned under international treaties.

The moves have sparked an unprecedented demand for legally grown, high quality marijuana, as well as the oil which is extracted from it. Seven Canadian producers have been granted licences to export the crop. By the end of March they will have sent 528 kilograms of dried cannabis flower and 911 litres of oil overseas. That may well be just an initial trickle, as the floodgates open on an international medical cannabis market.

“I’ve never experienced anything like this,” says Ranjeev Dhillon, a corporate lawyer and partner at the law firm Bennett Jones. Most of his practice now centres on the cannabis export business.

Brendan Kennedy of Tilray says Canada is the source of the safest product when regulators in other countries go looking for medical marijuana. (Evan Mitsui/CBC)

“I think it means that we’ll be a global player,” he says, stressing this is a positive development for the Canadian economy. “This could be our opportunity to be viewed the same as we are in mining or hockey. We’ll be world class and be world leaders and I think that will stay to be the case for a very, very long time.”

Medical research forcing an end to prohibition

For decades an international ban on the production and use of cannabis kept to a minimum any legitimate research into potential medical uses. Prohibition ensured that marijuana cultivation stayed in the hands of illegal growers, and distribution was limited to the criminal underground.

But many users saw value in cannabis as treatment for a variety of conditions, ranging from controlling epileptic seizures to pain relief to stress control.

Israeli scientist Raphael Mechoulam began limited research on the drug in the early 1960s, which led to the discovery of the human endocannabinoid system. By the mid-1990s, scientists determined that cannabinoid receptors play a vital role in the function of the human body. For the first time synthetic cannabinoid derivatives were approved for medical use, primarily for the treatment of nausea and wasting syndrome.

At the same time anecdotal evidence was building to suggest cannabis could have other, more widespread medical uses. Patients who claimed benefits from cannabis went to court seeking the right to use marijuana as medicine without facing the risk of criminal prosecution.

In 2000 the Ontario Court of Appeal ruled that Terry Parker, a man with severe epilepsy, should have the right to use marijuana to moderate his severe seizures.

One year later, Canada’s Medical Marijuana Access Program was introduced, allowing patients who had obtained a doctor’s consent to grow their own marijuana under a special permit. By 2013 more than 28,000 Canadians had been granted personal use production licences, leading to a flood of unregulated home-grow operations, and along with it a risk of fires, mould contamination in homes, and legally grown weed being diverted to the black market.

In an effort to crack down on the home grow-ops, the Harper Conservative government introduced new legislation that established legal grow operations which could provide medical marijuana through a mail order service. The Marijuana for Medical Purposes regulations, enacted in 2014, set Canada apart as the first nation to establish a regulated commercial cannabis cultivation industry.

Canadian pot finds a role in the world market

As Canada moves towards legal recreational weed in July, the number of licensed growers has swelled to 84, production is skyrocketing, and research into new growing techniques and improved strains is increasing exponentially. This has placed Canada in a unique role as other nations scramble to find safe and legal supplies of medical cannabis.

Cam Battley, executive vice president of Aurora, shows off Aurora Vie’s Pointe-Claire, Que., facility. Canadian producers have expertise in greenhouse technology, extraction methods, strains and genetics. (CBC)

“When regulators in other countries are looking for a product, Canada is really the source of the safest product. It’s the safest bet,” explains Brendan Kennedy, the CEO of Nanaimo-based Tilray, a pioneer in cannabis exports.

Tilray is among several Canadian producers already exporting to Germany, which established a widespread marijuana access program last spring. Not only is cannabis stocked in German pharmacies, the government pays for the drug under its government health insurance program.

Until it can establish a domestic industry, Germany is importing from Canada. Along with Tilray, Canadian producers Aurora, Cronos and Canopy Growth are tapping the German market. Aurora has even gone a step further, purchasing pharmaceutical supplier Pedanios, with an eye to expanding its distribution in the European market.

Following Germany, several other European countries, including Greece, Italy, Poland and the Czech Republic, passed new medical cannabis laws. Several others are following. A report published in November places the value of the European cannabis market at $84 billion Cdn a year.

That’s led Tilray to begin construction of a $30-million production facility in Portugal to help supply the growing market.

Beyond exports, Canada has expertise

“Part of the reason we decided to invest in a cultivation facility in Portugal was that we also saw a massive increase in demand for medical cannabis product in the EU,” explains Kennedy, who sees a bright future well beyond Canadian exports.

Canadian expertise in growing and greenhouse technology, extraction methods, strains and genetics, along with plain old business know-how, are also in demand. In addition to exports, Canada’s cannabis companies are also teaming up with local partners to build facilities in Germany, Denmark and Israel.

Australia is seen as another prize for Canadian producers. When it announced last February that it would allow importation, Canadian producers Aurora, CannTrust, Canopy, MedReleaf and Tilray swooped in, not only with bags of weed and vials of oil, but with partnerships to build facilities there.

Peru and Mexico have also passed legislation to legalize medical cannabis, and Canadian companies are promising further announcements soon. Overall, they say, the world market could be worth around $200 billion.

What it all means

The rapid legalization of medical cannabis has spurred new research into potential treatments using the drug. In Israel, where the medical research began, there are about 120 trials underway using components of the marijuana plant.

Neil Closner, CEO of Ontario-based MedReleaf, believes Canadian medical marijuana producers have the potential to become global giants. (Canadian Press)

As cures and treatments are discovered and proven, the role of cannabis is sure to expand, creating even greater potential beyond flowers and oil. CEO of Markham-based MedReleaf Neil Closner believes at least two or three of Canada’s producers will become global giants.

“I think overall who wins is Canada. I think we’ve got a leg up on the rest of the world, which is very exciting at a national level for us. I’d like to think that MedReleaf is strongly positioned to be one of the few handfuls of global winners.”

And while California is the latest U.S. state to legalize marijuana, American producers are shut out of the global market because of the federal prohibition on the drug.

That leaves Canada room to pursue the international market and all the potential riches that go with it.

Source: http://www.cbc.ca/news/business/medical-marijuana-canadian-export-1.4470407

Tetra Bio-Pharma $TBP.ca Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary $AERO $CBDS $CGRW $APH.ca $GBLX #CBD #Marijuana

Posted by AGORACOM-JC at 9:13 AM on Tuesday, January 2nd, 2018

Logo tetrabiopharma rgb web

  • Announced that it has entered into a share purchase agreement  with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation
  • Under the terms of the Purchase Agreement, Tetra will acquire from the Vendors all of the remaining issued and outstanding common shares of Tetra’s subsidiary, Phytopain Pharma Inc.

OTTAWA, ONTARIO–(Jan. 2, 2018) Tetra – Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the “Purchase Agreement“) with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Vendors“).

Under the terms of the Purchase Agreement, Tetra will acquire from the Vendors all of the remaining issued and outstanding common shares of Tetra’s subsidiary, Phytopain Pharma Inc. (“PPP“), currently held by the Vendors (representing 20% of the issued and outstanding shares of PPP) for an aggregate purchase price (the “Purchase Price“) of $12,425,089 (the “Transaction“). Upon completion of the Transaction, PPP will become a wholly-owned subsidiary of Tetra.

“Upon completion, this transaction will be a significant milestone for Tetra Bio-Pharma and all our stakeholders,” said Bernard Fortier, Tetra’s CEO.

“The two selling shareholders – our Chairman and our Chief Scientific Officer – are both committed to the long-term success of Tetra as evidenced by their agreement to accept shares in Tetra in lieu of an all- cash transaction. As well, a percentage of those shares are going to be released once certain key milestones for the company have been reached,” he said.

“This transaction will allow Tetra to gain 100% control of Phytopain Pharma, a key asset in the development of our pipeline of cannabinoid-based drugs and gives our company full flexibility to enter into other partnerships or agreements in the future.”

The Transaction is subject to customary closing conditions including, but not limited to, approval of the TSX Venture Exchange (“TSXV“) and any other approval that may be required by the TSXV.

The Transaction

Under the terms of the Purchase Agreement, the Purchase Price for the Transaction is comprised of the following:

  • Cash: An aggregate cash payment of $248,000 (the “Cash Payment“). Under the terms of the Purchase Agreement, the Cash Payment is payable in escrow as of the signature of the Purchase Agreement and has been paid to the Vendors’ legal counsel in trust for the Vendors pending receipt of approval for the Transaction from the TSXV. In addition, Tetra has agreed to pay the Vendors, immediately upon signature of the Purchase Agreement, a non-refundable amount of $200,000, payable out of the funds available for the Cash Payment, to induce the Vendors to provide an exclusivity of negotiation to the Purchaser for the Transaction.
  • Promissory Notes: Promissory notes issued by Tetra to the Vendors in an aggregate principal amount of $2,236,696 (the “Notes“), which Notes are payable in accordance with a specified milestone schedule as described in the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, the Notes have been delivered to the Vendors’ legal counsel in trust for the Vendors pending receipt of approval for the Transaction from the TSXV.
  • Tetra Shares: Common shares of Tetra (“Common Shares“) will be issued to the Vendors as follows:
    • Upon completion of the Transaction, an aggregate of 2,485,218 Common Shares will be issued to the Vendors.
    • Upon completion of the Transaction, 7,455,653 Common Shares will be issued to
      Computershare Trust Company of Canada, as escrow agent (the “Escrow Agent“), to be held in escrow and released by the Escrow Agent under the terms and conditions set forth in the Purchase Agreement and the terms and conditions of an escrow agreement to be executed at closing by the Vendors, the Corporation and the Escrow Agent.

The Vendors under the Purchase Agreement are entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation and are therefore considered “non-arm’s length parties” under the rules of the TSXV. Mr. Rancourt and Mr. Chamberland have properly disclosed their respective interest in the Transaction to the board of directors of the Corporation.

The Transaction constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”). While MI 61-101 would generally subject the transaction to minority shareholder approval and formal valuation requirements, the Corporation will avail itself of the exemptions applicable under Section 5.5(a) of MI 61- 101.

Mr. Rancourt currently has ownership or direction and control over (i) an aggregate of 465,000 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 0.37% of the issued and outstanding Common Shares on a non- diluted basis and approximately 4.66% of the issued and outstanding Common Shares on a partially diluted basis. Further to the completion of the Transaction, and assuming that all of the Common Shares issued in escrow and allotted to Mr. Rancourt are released to Mr. Rancourt or an affiliate of Mr. Rancourt in accordance with the Purchase Agreement, Mr. Rancourt would then have ownership or direction and control over (i) 5,435,436 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 4.20% of the issued and outstanding Common Shares on a non-diluted basis and approximately 8.17% of the issued and outstanding Common Shares.

Mr. Chamberland currently has ownership or direction and control over (i) an aggregate of 1,250,000 Common Shares, (ii) 350,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 1.00% of the issued and outstanding Common Shares on a non-diluted basis and approximately 4.32% of the issued and outstanding Common Shares on a partially diluted basis. Further to the completion of the Transaction, and assuming that all of the Common Shares issued in escrow and allotted to Mr. Chamberland are released to Mr. Chamberland or an affiliate of Mr. Chamberland in accordance with the Purchase Agreement, Mr. Chamberland would then have ownership or direction and control over (i) 6,220,436 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 4.78% of the issued and outstanding Common Shares on a non-diluted basis and approximately 8.70% of the issued and outstanding Common Shares.

Each of Mr. Rancourt and Mr. Chamberland proposes to acquire the common shares for investment purposes, and has no current intention to increase his beneficial ownership of, or control or direction over, securities of Tetra. These investments will be reviewed on a continuing basis and their holdings may be increased or decreased in the future.

The Transaction is subject to customary conditions including, but not limited to, approval of the TSXV. The Transaction has been unanimously approved by Tetra’s board of directors (with André Rancourt abstaining from voting) and Tetra anticipates that the Transaction will be completed in the first quarter of 2018.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Corporation, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princepsproduct offering and inhalation device; guidance on expected sales volumes associated with the Rx Princepsproduct offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Bernard Fortier, MBA
Chief Executive Officer
(514) 360-8040 Ext. 206
bernard.fortier@tetrabiopharma.com
www.tetrabiopharma.com

Tetra Bio-Pharma $TBP.ca Announces the Signature of a Letter of Intent to Monetize #GrowPros and its Late Stage ACMPR Application $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:38 AM on Thursday, December 21st, 2017

Logo tetrabiopharma rgb web

  • Entered into a non-binding letter of intent with a private Canadian corporation and has started a transaction to monetize GrowPros to allow Tetra to focus its activities on the drug development and its clinical trials of its pharmaceutical business

OTTAWA, ONTARIO–( Dec. 21, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI“) with a private Canadian corporation (the “Purchaser“) and has started a transaction to monetize GrowPros (GrowPros MMP Inc., Tetra’s wholly-owned subsidiary) (the “Potential Transaction“), to allow Tetra to focus its activities on the drug development and its clinical trials of its pharmaceutical business. With this transaction, Tetra is expected to receive $350,000 and ensure another supply source of cannabis with pharmaceutical GMP quality for the pipeline of products under development.

It is expected that the Proposed Transaction would include the following main terms:

  • Acquisition by the Purchaser of all the issued and outstanding shares of GrowPros held by the Company;
  • Tetra will receive $350,0000 for the Potential Acquisition composed of (i) a first installment of $175,000 which was paid at the time of the signing of the LOI, (ii) a second installment of $175,000 which will be paid following signing of the definitive agreement giving effect to the LOI (the “Definitive Agreement“) and (iii) subject to stock exchange and securities regulatory approval and following the Purchaser’ initial public offering, 15,000,000 common shares of the Purchaser which would represent approximately a 33% equity interest in the share capital of the Purchaser post-initial public offering. The intention is for Tetra to eventually distribute these shares as a dividend in kind to its shareholders on a pro-rated basis;
  • Purchaser’s responsibility to move GrowPros’ late stage ACMPR application forward (submitted in November 2014) with Health Canada;
  • Grant by Purchaser and GrowPros of a right of first refusal to the Company on future cannabis production by GrowPros, which will ensure a second source of cannabis to the Company with pharmaceutical GMP quality for the production of the pipeline of products under development;
  • Undertaking by the Purchaser to build a 15,000 square feet production facility located on 145 acres of agricultural land in Venosta, Quebec. The property has been approved for up to 1.5M square feet of production space; the Purchaser will ensure that a dedicated part of that production facility will be in compliance with good manufacturing practices for pharmaceutical product; construction of the production facility is expected to begin in the first quarter of 2018.

“We are very happy to leverage this asset that is Grow Pros. By finding a reliable partner, Tetra expects not only to immediately increase its cash flow, but also to enable its shareholders to maintain an investment in the high growth cannabis industry. As importantly, Tetra is further focusing on its core expertise and strength: the development of prescription drugs through the highest levels of clinical trials. Finally, we expect this deal to allow us to secure our production of dried cannabis for our lead drug candidate for its expected approval and eventual commercialization, and provide us with another partner from which we can supply our active pharmaceutical ingredients (API) for our drug development programs.” says Bernard Fortier, CEO of Tetra.

The Proposed Transaction contemplated by the LOI is subject to a number of significant condition precedents including but not limited to the entering into of the Definitive Agreement on terms satisfactory to both parties, the completion of the Purchaser’s initial public offering and receipt of all requisite approval (including stock exchange and regulatory approvals).

The parties intend to enter into the Definitive Agreement and close the Proposed Transaction by the end of the first quarter of 2018.

About Tetra Bio-Pharma: 

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Forward-looking statements 

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com

World Health Group: Pot’s #CBD Has Health Benefits #Marijuana $MCOA $N.ca $TBP.ca $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 4:25 PM on Tuesday, December 19th, 2017
  • Compound found in the cannabis plant is not harmful, has health benefits, and does not have abuse potential, experts at the World Health Organization say.
  • WHO’s Expert Committee on Drug Dependence focused on cannabidiol, or CBD, one of the naturally occurring cannabinoids found in cannabis plants

After reviewing evidence from animal and human studies, the committee concludes that “In humans, CBD exhibits no effects indicative of any abuse or dependence potential.”

Slideshow: Medical Marijuana

1/10

What Is Medical Marijuana?

Medical marijuana is any part of the marijuana plant that you use to treat health problems. People use it to get relief from their symptoms, not to try to get high.

Most marijuana that’s sold legally as medicine has the same ingredients as the kind that people use for pleasure. But some medical marijuana is specially grown to have less of the chemicals that cause feelings of euphoria.

The experts also say that CBD might be able to treat epilepsy (where most research has focused), although results are mixed. Other conditions it might treat are Alzheimer’s disease, Parkinson’s, anxiety, depression, and other maladies. CBD may ease inflammation, provide antioxidants, and relieve pain.

Based on its research, the committee concluded that current information does not call for scheduling of the drug. In the U.S., CBD is a Schedule 1 controlled substance. These are defined as drugs with no medical use and likely to be abused.

Twenty-nine states and Washington, D.C., have legalized the use of marijuana for recreational or medicinal purposes. Other states, including Georgia, have legalized the possession of CBD to treat specific disorders.

It remains a federal crime, however, to have or sell any form of marijuana, including CBD. Despite those federal regulations, CBD is an ingredient in popular products sold over the counter as oils, extracts, supplements, and gum to treat many ailments.

CBD usually is given as a capsule or dissolved in liquid to be taken orally, under the tongue, or as a nasal spray. CBD does not produce the high that another cannabinoid — tetrahydrocannabinol (THC) — does, experts say. In fact, CBD appears to have effects opposite of THC.

The WHO announcement drew a positive response from marijuana advocates and criticism from those who don’t want it to be legal.

The experts produced the report in November, while the WHO announced its conclusions this week. In May, the committee will study cannabis and cannabis-related substances more fully.

Other major studies have shown marijuana and its products can relieve pain, nausea related to cancer treatment, and multiple sclerosis-related muscle spasms. But using cannabis has well-known short-term and long-term health effects, such as learning and coordination problems.

Because federal law makes it a crime to have marijuana and CBD, researchers must pass strict government scrutiny just to study its usefulness.

DEA View of CBD

The conclusion of the WHO flies in the face of the view of the U.S. Drug Enforcement Administration (DEA). It says that CBD must be treated the same as THC and other cannabinoids from a cannabis plant, and it should remain a Schedule I drug.

NORML Response

Marijuana advocates applauded the WHO’s conclusion. “It was terrific to see WHO acknowledge what other scientific research has already stated,” says Justin Strekal, political director of the National Organization for the Reform of Marijuana Laws (NORML).

In an email statement, he adds: “While we are pleased to see the WHO finally acknowledge that absurdity of international restrictions, the continued domestic classification and criminalization of cannabidiol as a Schedule I controlled substance is out of step with both available science and common sense. It is yet another example of the U.S. government placing ideology over evidence when it comes to issues related to the cannabis plant.”

CALM Response

Scott Chipman, Southern California chairman of Citizens Against Legalizing Marijuana (CALM), took issue with the report.

“We need to maintain a strict scientific perspective and protocols when it comes to new drugs,” he says. “We need double-blind studies related to marijuana and all components, research on the harms versus the benefits, identification of the side effects and specific ailments identified through these studies — even for CBD,” he says.

He says some ongoing drug studies of CBD do show promise in treating seizure disorders, but he also sees potential problems with the drugs, along with concerns about contamination and other potential harms with over-the-counter products.

Source: https://www.webmd.com/a-to-z-guides/news/20171215/world-health-group-pots-cbd-has-health-benefits

Tetra Bio-Pharma $TBP.ca Opens the Market $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 2:31 PM on Wednesday, December 6th, 2017

Logo tetrabiopharma rgb web

  • Bernard Fortier, CEO, Tetra Bio-Pharma Inc. (TBP), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market

TORONTO, Dec. 5, 2017 – Bernard Fortier, CEO, Tetra Bio-Pharma Inc. (TBP), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market. Tetra Bio-Pharma biopharmaceutical company that is engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements. Tetra Bio-Pharma Inc. commenced trading on TSX Venture Exchange on August 16, 2017.

SOURCE TMX Group Limited

Aphria $APH.ca to supply medical marijuana to Shoppers Drug Mart $N.ca $TBP.ca $MCOA

Posted by AGORACOM-JC at 1:19 PM on Tuesday, December 5th, 2017
  • Aphria Inc struck a deal to sell medical marijuana to Shoppers Drug Mart, Canada’s largest pharmacy chain
  • “Subject to Health Canada’s approval of Shoppers Drug Mart’s application to be a licensed producer, under the terms of the agreement the Company will supply Shoppers Drug Mart with Aphria-branded medical cannabis products,” a release from Aphria said. “It is expected the products will be sold online, as Canadian regulations currently restrict the sale of medical cannabis in retail pharmacies.”

Shoppers, or its parent company, Loblaw Companies Ltd., have not been issued a licence to dispense cannabis yet, according to Health Canada’s list of companies registered to grow and sell medical marijuana. It was reported in November that Shoppers was searching for someone to serve as the pharmacy chain’s medical marijuana brand manager.

Vic Neufeld, chief executive of of Aphria, said his company had a five-year agreement with Shoppers as its “first and primary supplier,” and that every year of the deal included “minimum requirements on volumes that they must purchase from us for them to maintain the following year’s exclusivity.”

Based on the terms of the agreement, specific financial terms would not be disclosed, he said.

“This stems from our long-held belief that pharmacies can, and should, play an important role in the safe and secure distribution of medical cannabis in Canada,” Neufeld added on a conference call with analysts. “It gives Aphria a huge, huge lift when it comes to the shareholder value.”

Trading of Aphria shares was halted Monday afternoon, with the company’s stock price closing up 1.93 per cent, at $11.62. Shares of the greenhouse grower are up nearly 86 per cent for the year.

The supply agreement between Aphria and Shoppers has been reached approximately seven months out from Canada’s July 2018 target date for the legalization of recreational cannabis. It also follows Saskatchewan-based medical marijuana company CanniMed Therapeutics Inc. becoming the first licensed producer to sign a deal with a national pharmacy chain when it signed a letter of intent with PharmaChoice in March of this year.

Neufeld said that during the “many months” of conversations with Shoppers, they had only discussed medical marijuana sales, not recreational.

Neufeld also said the form of “exclusivity” Aphria had given Shoppers does not restrict the pharmacy from considering “other forms of intake products, medical devices by way of example.”

“However, there is an understanding that should we be able to service their needs we would be given an opportunity to bid on it,” Neufeld added.

According to Aphria’s most recent results, for the quarter ended Aug. 31, the company reported net income of $15 million and a 15 per cent increase in sales, to 852 kilograms or kilograms equivalent of cannabis.

“For a period of time, we will not engage in any other conversations or business transactions with other national pharmacy banners in excess of a certain size,” Neufeld said. “Have we excluded certain banners? Yes, however, for us it was very important to get Canada’s leading banner in alignment with the Aphria business model, and so that’s what we agreed to.”

gzochodne@nationalpost.com
Twitter: @geoffzochodne

Source: http://business.financialpost.com/commodities/ontario-cannabis-company-aphria-to-supply-medical-marijuana-to-shoppers-drug-mart

Canadian #Marijuana awards show lights up with first-ever gala #MMJ $TBP.ca $N.ca $MCOA

Posted by AGORACOM-JC at 10:48 AM on Thursday, November 30th, 2017
  • You know marijuana is going mainstream when the list of attendees who reserved tables reads like a who’s who of Canada’s haze of law and accounting firms, including Torys LLP, Dentons, Cassels Brock & Blackwell LLP, Bennett Jones LLP, investment dealer Eight Capital and accounting giants KPMG and MNP
By Lisa WrightBusiness Reporter
Wed., Nov. 29, 2017

What do you do if you’re a budding awards show trying to create a buzz around Canada’s $8.7-billion cannabis market?

First you weed out the best producers from the very large crop of products out there. Then you book a swanky joint and roll out the red carpet for business types looking to get in on the potential pot of gold surrounding legalization next summer.

The CEO of Lift Co., the online marketplace for the medical marijuana industry that is holding the event, says it was high time for a grass gala to highlight the fourth annual Canadian Cannabis Awards – previously held only online – in an effort to add some legitimacy to the often stigmatized cannabis community.

“It’s really going to be a mini Oscars” of pot, said Matei Olaru of the awards show being held Thursday night at the historic Carlu at College Park.

You know marijuana is going mainstream when the list of attendees who reserved tables reads like a who’s who of Canada’s haze of law and accounting firms, including Torys LLP, Dentons, Cassels Brock & Blackwell LLP, Bennett Jones LLP, investment dealer Eight Capital and accounting giants KPMG and MNP.

“These are recognizable names excited to be associated publicly with the industry,” said Olaru.

“The industry has matured enough and there are enough players, so it’s the right time for this,” he added.

In fact they will hand out a whopping 75 awards to producers and numerous other players in the marijuana business during an evening of cocktails and plenty of munchies over a sit-down dinner. The laughs will officially be provided by famed comedian twins The Lucas Brothers of 22 Jump Street and Netflix fame, who will be performing standup before the after party.

Categories range from the traditional — employer of the year, startup of the year, innovator of the year, deal of the year and even lifetime achievement award — to the offbeat, including the best in show of vape lounges, cannabis chefs, desktop and portable vaporizers, top testing lab and best home growing box.

“It’s a way to showcase those achievements,” said Olaru, whose mission is to demystify the continued confusion around the medical marijuana market as it grows like a weed.

For instance pot smoking rapper Snoop Dogg recently partnered with Canadian licensed producer Tweed, which is nominated in multiple categories.

Another sign that legalization is around the corner is Lift landing official support this week from MADD Canada as it develops Canada’s first retail training certification program for frontline staff at cannabis retailers who will have legal storefronts as of July 2018.

“Our experience with alcohol sales has shown that having comprehensive training and responsible service guidelines for front-line staff is crucial to reducing alcohol-related harms, including impaired driving,” says MADD Canada chief executive officer Andrew Murie.

“The same will be true of cannabis retail sales. MADD Canada is pleased to partner with a leader like Lift and support this program, which will ensure that all those involved in the retail sales of cannabis are well-trained about the products, about safe usage guidelines and about social responsibility principles,” he said in a release.

Source: https://www.thestar.com/business/2017/11/29/canadian-marijuana-awards-show-lights-up-with-first-ever-gala.html

ThreeD Capital Inc. $IDK.ca Acquires Securities of Global Cannabis Applications Corp.$APP.ca $ATT.ca $ABCN.ca $ACG.ca $ACB

Posted by AGORACOM-JC at 9:36 AM on Wednesday, November 29th, 2017

Threed capital

  • Acquired ownership and control of an aggregate of 1,000,000 common shares and 1,000,000 common share purchase warrants of Global Cannabis Applications Corp. 
  • Immediately before the transaction described above, ThreeD and the Joint Actor held an aggregate of 4,850,000 common shares of the Company, and convertible securities entitling ThreeD and the Joint Actor to acquire an additional 2,250,000 common shares of the Company

TORONTO, Nov. 29, 2017 – ThreeD Capital Inc. (“ThreeD”) (CSE:IDK) is pleased to announce that it has acquired ownership and control of an aggregate of 1,000,000 common shares (the “Subject Shares”) and 1,000,000 common share purchase warrants (the “Subject Warrants” and together with the Subject Shares, the “Subject Units”) of Global Cannabis Applications Corp. (the “Company”) on November 28, 2017.  The Subject Units represented approximately 1.7% of all issued and outstanding common shares of the Company as of November 28, 2017 immediately following the transaction described above (or approximately 3.4% on a partially diluted basis, assuming exercise of the Subject Warrants only), resulting in a corresponding increase in the percentage of shares held by ThreeD and its Joint Actor as a result of the transaction.

Immediately before the transaction described above, ThreeD and the Joint Actor held an aggregate of 4,850,000 common shares of the Company (the “Pre-Shares”), and convertible securities entitling ThreeD and the Joint Actor to acquire an additional 2,250,000 common shares of the Company (the “Pre-Convertible Securities”) representing approximately 9.0% of the issued and outstanding common shares of the Company (or approximately 12.6% on a partially diluted basis, assuming exercise of the Pre-Convertible Securities only).  Of this total, ThreeD held an aggregate of 3,000,000 of the Pre-Shares and 2,000,000 Pre-Convertible Securities, representing approximately 5.6% of the issued and outstanding common shares of the Company (or approximately 8.9% assuming exercise of such Pre-Convertible Securities only), and the Joint Actor held an aggregate of 1,850,000 of the Pre-Shares and 250,000 Pre-Convertible Securities, representing approximately 3.4% of the issued and outstanding common shares of the Company (or approximately 3.9% on a partially diluted basis, assuming exercise of such Pre-Convertible Securities only).

Immediately following the transaction described above, ThreeD and the Joint Actor held an aggregate of 5,850,000 common shares (the “Post-Closing Shares”) and convertible securities entitling ThreeD and the Joint Actor to acquire an additional 3,250,000 common shares of the Company (the “Post-Closing Convertible Securities”), representing approximately 10.2% of the issued and outstanding common shares of the Company (or approximately 15.0% assuming exercise of such Post-Closing Convertible Securities only).  Of this total, ThreeD held an aggregate of 4,000,000 of the Post-Closing Shares and 3,000,000 of the Post-Closing Convertible Securities (representing approximately 7.0% of the issued and outstanding common shares of the Company, or approximately 11.6% assuming exercise of such Post-Closing Convertible Securities only), and the Joint Actor held an aggregate of 1,850,000 of the Post-Closing Shares and 250,000 of the Post-Closing Convertible Securities, representing approximately 3.2% of the issued and outstanding common shares of the Company (or approximately 3.6% on a partially diluted basis, assuming exercise of such Post-Convertible Securities only).

The Subject Units were acquired in a private placement and not through the facilities of any stock exchange.  The holdings of securities of the Company by ThreeD and the Joint Actor are managed for investment purposes, and ThreeD and the Joint Actor could increase or decrease their investments in the Company at any time, or continue to maintain their current investment position, depending on market conditions or any other relevant factor. The aggregate consideration payable for the Subject Units was $135,000, or $0.135 per Subject Unit.

The trade was effected in reliance upon the exemption contained in Section 2.3 of National Instrument 45-106 on the basis that each of ThreeD and the Joint Actor is an “accredited investor” as defined herein.

About ThreeD Capital Inc.

ThreeD Capital Inc. is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources, Artificial Intelligence and Blockchain sectors.

ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services, mentoring and access to the Company’s network in order to earn increases to the Company’s equity stake.

For further information: Gerry Feldman, CPA, CA Chief Financial Officer and Corporate Secretary
Feldman@threedcap.com Phone: 416-606-7655